Respiratory Syncytial Virus

8RSV79

MA 104 cells, inoculated with Respiratory syncytial virus, strain Long.

Virus was grown on monolayer of MA cells. When the cultures showed pronounced c.p.e. virus containing medium was purified from cell fragments by low speed centrifugation (4000 rpm, 40 min). Virus was pelleted by high speed centrifugation at 18000 rpm for 2.5 hours in the SW27 rotor. The virus pellet was collected, diluted with STE buffer and layered over linear 30 to 60 % sucrose gradient prepared in STE buffer. The sample was recentrifuged at 25000 rpm in SW27 rotor for 2.5 h at + 4 °C, and then the virus band was collected, diluted with STE buffer and pelleted by centrifugation at 30000 rpm for 1.5 h at + 4 °C. The pellet of virus was collected and diluted in STE buffer.

STE, 0.09 % sodium azide (NaN₃) and 0.005 % of thimerosal.

Thimerosal and beta propiolactone treatment

This product has been treated in a manner consistent with methods of inactivation. Generally accepted good laboratory practices appropriate to microbiological/viral safe handling practices and techniques are required at work.

Purity > 90 %

Tested with anti-respiratory syncytial virus antibodies (Cat. # 3ReS21) in ELISA.

-20 °C (-15 … -30 °C allowed)

This product is sold for research or further manufacturing use only. Standard Laboratory Practices should be followed when handling this material.

Product contains thimerosal and sodium azide as a preservative. Although the amounts are very small appropriate care must be taken when handling this product.